Daewoong Pharmaceutical said on May 15 that its homegrown botulinum toxin "Nabota" (Jeuveau TM) was officially launched in the U.S.
Jeuveau was the first Korean-made botulinum toxin to win approval for an item license from the U.S. Food and Drug Administration in February. Jeuveau's local sales in the U.S. will be taken up by Evolus, Daewoong Pharmaceutical's partner company.
Through "The Jeuveau Experience Treatment (J.E.T.)," which offers product experience opportunities, Evolus will showcase Jeuveau to more than 3,000 local medical staff in the U.S. starting May 15.
"Jeuveau's launch in the U.S. is a triumph that has raised Daewoong Pharmaceutical's status as well as raised the status of domestic pharmaceuticals," said Park Sung-soo, head of Daewoong Pharmaceutical's Nabota business. "I am very pleased that Daewoong Pharmaceutical's products have made its way into the United States, the world's largest market for botulinum toxin."
Meanwhile, Daewoong Pharmaceutical is also set to enter Europe, the world's second largest market for botulinum toxin, following the U.S. market.
In April, the Committee for Medical Products for Human Use (CHMP) under the EMA issued a "license approval" for Nuceiva TM's European sales permit. It is expected to be the first Korean-made botulinum toxin medicine to enter the U.S. and Europe at the same time.
